Kelly Gold - 31 Aug 2026 Form 4 Insider Report for Camp4 Therapeutics Corp (CAMP)

Reporting relationship: Chief Financial Officer
Issuer ticker: CAMP
Reported as of: 31 Aug 2026
Net transaction value: +$39,600
SEC form: 4
Accepted by SEC: 02 Sep 2026, 19:50:12 UTC
Prior SEC filing: 05 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Kelly Gold

Key filing fact

Kelly Gold filed Form 4 for Camp4 Therapeutics Corp (CAMP) on 02 Sep 2026.

Key facts

This page summarizes Kelly Gold's Form 4 filing for Camp4 Therapeutics Corp (CAMP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Sep 2026, 19:50.

Change

Previous filing in this sequence was filed on 05 Aug 2026.
Current net transaction value: +$39,600.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002033333 Primary reporting owner

Gold Kelly

Relationship: Chief Financial Officer
Address: C/O CAMP4 THERAPEUTICS CORPORATION, 100 TALCOTT AVE., SUITE 201, WATERTOWN
Signature: /s/ Kelly Gold
Signature date: 02 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAMP transaction

Common Stock

Purchase

Transaction value: $39,600
Shares: +10,000
Change %
Price: $3.96
Shares after: 10,000
Date: 31 Aug 2026
Ownership: By Spouse
Footnotes: F1, F2

CAMP holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 76,467
Date: 31 Aug 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares reported herein were purchased in the open market in multiple transactions at prices ranging from $3.88 to $4.00, inclusive. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to CAMP4 Therapeutics Corporation, any security holder of CAMP4, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Footnote F2

The shares reported herein are held in a brokerage account in the name of David Gold, the Reporting Person's spouse. The Reporting Person does not exercise investment control over this account. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.

Footnote F3

Includes 2,039 shares previously acquired by the reporting person pursuant to the CAMP4 Therapeutics Corporation Employee Stock Purchase Plan (the "ESPP") in a transaction that was exempt under Rule 16b-3(c).